SF
RARE icon

Synovus Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Synovus Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-49
Closed -$2K – 2012
2020
Q1 		$2K Hold
49
– – ﹤0.01% 1969
2019
Q4 		$2K Buy
+49
New +$2.02K ﹤0.01% 1435

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Synovus Financial's RARE Position: Q2 2020 in Review

Synovus Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2020, closing a stake of 49 shares — an estimated $2K sold.

Synovus Financial first reported a position in RARE in Q4 2019 and held it in 2 quarters. The position peaked at $2K in Q1 2020. 192 funds tracked by Wall St. Rank hold RARE as of Q2 2020.

  • Synovus Financial reported no remaining Ultragenyx Pharmaceutical position as of Q2 2020 after selling out during the quarter.
  • Synovus Financial sold 49 Ultragenyx Pharmaceutical shares in Q2 2020, an estimated $2K.
  • Synovus Financial first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 2 quarters.
  • Synovus Financial's Ultragenyx Pharmaceutical position peaked at $2K in Q1 2020.
  • 192 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2020.

Based on Synovus Financial's 13F filing for Q2 2020, filed 10 Aug 2020.